Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases:Use of the Landmark Method
10.3349/ymj.2021.62.11.997
- Author:
Yoon Young CHOI
1
;
Jung Kuk LEE
;
Hyun-Soo KIM
;
Dong Wook KIM
;
Hee Man KIM
;
Dae Ryong KANG
Author Information
1. Artificial Intelligence Big Data Medical Center, Wonju College of Medicine, Yonsei University, Wonju, Korea
- Publication Type:Original Article
- From:Yonsei Medical Journal
2021;62(11):997-1004
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to determine whether the use of drugs in the treatment of inflammatory bowel disease is related to the risk of colorectal cancer using a Cox proportional hazards model with the landmark method to minimize immortal time bias.
Materials and Methods:This study was conducted as national cohort-based study using data from Korea’s Health Insurance Corporation. Newly diagnosed patients with inflammatory bowel disease from 2006 to 2010 were monitored for colorectal cancer until 2015. Hazard ratios and 95% confidence intervals were calculated and compared with the incidence of colorectal cancer with or without medications by applying various landmark points.
Results:In patients with Crohn’s disease, the prevention of colorectal cancer in the group exposed to immunomodulators was significant in the basic Cox model; however, the effect was not statistically significant in the model using the landmark method. The preventive effect of 5-aminosalicylic acid in patients with ulcerative colitis was significant in the basic and 6-month landmark point application models, but not in the remaining landmark application models.
Conclusion:In patients with inflammatory bowel disease, the preventive effect of drug exposure on colorectal cancer varies depending on the application of the landmark method. Hence, the possibility of immortal time bias should be considered.
